[Hematological toxicity and nandrolone decanoate during polychemotherapy of bronchogenic carcinoma. Preliminary note].
D000368:Aged; D045930:Anabolic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001773:Blood Cells / Q000187:drug effects*; D001853:Bone Marrow / Q000187:drug effects*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077603:Nandrolone Decanoate; D014747:Vinblastine / Q000008:administration & dosage
D045930:Anabolic Agents; D014747:Vinblastine; D009277:Nandrolone; D003520:Cyclophosphamide; D000077603:Nandrolone Decanoate; D002945:Cisplatin
Tossicità ematologica e nandrolone decanoato in corso di polichemioterapia per carcinoma broncogeno. Nota preliminare.